Clinical Trial Update: Study to Evaluate Efficacy of OLX10010 in Reducing Recurrence of Hypertrophic Scarring After Scar Revision Surgery [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating OLX10010 for reducing recurrence of hypertrophic scars after scar revision surgery has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertrophic Scar

Drugs mentioned

• OLX10010

Snippet

Sponsor: Olix Pharmaceuticals, Inc. | Conditions: Hypertrophic Scar | Phase 2 | Status: COMPLETED